Kronos Bio Reports Recent Business Progress and First-Quarter 2023 Financial Results

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML... | May 10, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Sarah Connors ,Norbert Bischofberger ,Kronos Bio ,Roger Dansey ,Leo Vartorella David Rosen ,Katherine Vega Stultz ,Claudia Styslinger ,Bristol Myers Squibb ,Gilead Sciences ,Company Updates ,Merck Co Inc ,Exchange Commission ,Amgen ,Corporate Communications ,Kronos Bio Inc ,Company Contact ,Development Of Seagen Inc ,Linkedin ,Genentech ,Eli Lilly Company ,Nasdaq ,Vega Stultz ,Recent Company Updates ,Chief Executive Officer ,Chief Operating Officer ,Graphite Bio ,Eli Lilly ,Senior Vice President ,Cash Equivalents ,San Mateo ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Report ,Vice President ,Investor Relations ,Nc Stock Exchange ,News ,Information ,Press Release ,Enrollment ,Ngoing ,N ,Expansion ,Portion ,F ,Hase ,Ith ,Nitial ,Efficacy ,Data ,Xpected ,Mh ,023 ,Study ,Anraplenib ,Combination ,Gilteritinib ,N Kron Us50107a1043 ,